2023-07-21 18:54:00
“Abryso is the first-ever RSV vaccine indicated for passive immunization of infants from birth until six months following being administered to the mother during pregnancy,” the EMA press release said. “The vaccine is also suitable for the active immunization of adults aged 60 and over.” RSV is a virus that affects the lower respiratory tract. Its symptoms resemble those of a cold. However, this virus can cause complications and even prove fatal, mainly for young children and the elderly. In Europe, it is one of the main reasons for infant hospitalizations. The disease is common worldwide and occurs seasonally, in October and April in the northern hemisphere, in May and October in the southern hemisphere. (Belga)
© 2023 Belga Newsbriefing. All rights of reproduction and representation reserved. All the information reproduced in this section (dispatches, photos, logos) is protected by intellectual property rights held by Belga Newsbriefing. Consequently, none of this information may be reproduced, modified, redistributed, translated, commercially exploited or reused in any way whatsoever without the prior written consent of Belga Newsbriefing.
1689966903
#Green #light #RSV #vaccine #infants
